Imiglucerase

Brand names: Cerezyme®

Last updated: 7/1/2002

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

Imiglucerase
Systematic (IUPAC) name
Human Beta-glucocerebrosidase
Identifiers
CAS number	143003-46-7
ATC code	A16AB02
PubChem	?
DrugBank	BTD00026
Chemical data
Formula	C2532H3854N672O711S16
Mol. mass	55597.4 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	3.6-10.4 min
Excretion	?
Therapeutic considerations
Licence data	EU EMEA:link, US FDA:link
Pregnancy cat.	?
Legal status
Routes	Intravenous

Imiglucerase is a medication used in the treatment of Gaucher's disease.^[1][2]

It is a recombinant DNA-produced analogue of human β-glucocerebrosidase. Cerezyme is a freeze-dried medicine containing imiglucerase, manufactured by Genzyme Corporation. It is given intravenously after reconstitution as a treatment for Type 1 Gaucher's disease. It is available in formulations containing 200 mg per vial and 400 mg per vial. It is one of the most expensive drugs sold, with an annual cost to U.S. patients of $200,000^[3]

See also

• Other drugs for the treatment of Gaucher's disease
  • Isofagomine tartrate
  • Miglustat

References

1. ^ Weinreb NJ (August 2008). "Imiglucerase and its use for the treatment of Gaucher's disease". Expert Opin Pharmacother 9 (11): 1987–2000. doi:10.1517/14656566.9.11.1987. PMID 18627336. http://www.expertopin.com/doi/abs/10.1517/14656566.9.11.1987. 
2. ^ Starzyk K, Richards S, Yee J, Smith SE, Kingma W (February 2007). "The long-term international safety experience of imiglucerase therapy for Gaucher disease". Mol. Genet. Metab. 90 (2): 157–63. doi:10.1016/j.ymgme.2006.09.003. PMID 17079176. http://linkinghub.elsevier.com/retrieve/pii/S1096-7192(06)00297-6. 
3. ^ Balancing innovatino, access, and profits -- marketing exclusivity for biologics, Alfred B. Engelberg et al., N Engl J Med 361:1917

v • d • e Other alimentary tract and metabolism products (A16) Amino acids and derivatives Levocarnitine • Ademetionine • Levoglutamide • Mercaptamine • Carglumic acid • Betaine Enzymes Carbohydrate metabolism: sucrase (Sacrosidase) • alpha-glucosidase (Alglucosidase alfa) Glycolipid/sphingolipid: glucocerebrosidase (Alglucerase, Imiglucerase) • alpha-galactosidase (Agalsidase alfa, Agalsidase beta) Glycosaminoglycan: iduronidase (Laronidase) • arylsulfatase B (Galsulfase) • iduronate-2-sulfatase (Idursulfase) Various alimentary tract and metabolism products Tioctic acid • Anethole trithione • Sodium phenylbutyrate • Nitisinone • Zinc acetate • Miglustat • Sapropterin

This pharmacology-related article is a stub. You can help Wikipedia by expanding it. v • d • e

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)